de Diego; Heidi Lopez

Patent Applications and Registrations

Patent applications and USPTO patent grants for de Diego; Heidi Lopez.The latest application filed is for "solid forms of (2s,3s,4s,5r,6s)-3,4,5-trihydroxy-6-(((4ar,10ar)-7-hydroxy-1-propyl-1,2,3- ,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2h-pyran-2-ca- rboxylic acid".

Company Profile

4.16.13

de Diego; Heidi Lopez - N.ae butted.rum DK
de Diego; Heidi Lopez - Valby DK
de Diego; Heidi Lopez - Naerum DK

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Vortioxetine pyroglutamate Grant 11,279,682 - de Diego , et al. March 22, 2	2022-03-22
Solid Forms Of (2s,3s,4s,5r,6s)-3,4,5-trihydroxy-6-(((4ar,10ar)-7-hydroxy-1-propyl-1,2,3- ,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2h-pyran-2-ca- Rboxylic Acid App 20220024962 - Jensen; Klaus Gjervig ; et al.	2022-01-27
Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3- ,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-ca- rboxylic acid Grant 11,130,775 - Jensen , et al. September 28, 2	2021-09-28
Solid Forms Of (2s,3s,4s,5r,6s)-3,4,5-trihydroxy-6-(((4ar,10ar)-7-hydroxy-1-propyl-1,2,3- ,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2h-pyran-2-ca- Rboxylic Acid App 20200392176 - Jensen; Klaus Gjervig ; et al.	2020-12-17
Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]-piperazine Grant 10,857,149 - Treppendahl , et al. December 8, 2	2020-12-08
Vortioxetine Pyroglutamate App 20190210987 - de Diego; Heidi Lopez ; et al.	2019-07-11
Liquid Formulations of Salts of 1-[2-(2,4-Dimethylphenylsulfanyl)Phenyl]-Piperazine App 20190167667 - Treppendahl; Svend ; et al.	2019-06-06
Vortioxetine pyroglutamate Grant 10,287,261 - de Diego , et al.	2019-05-14
Polymorphic form of N-[2-(6-fluoro-1H-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzyla- mine hydrochloride for the treatment of Alzheimer's disease Grant 10,071,963 - Andersen , et al. September 11, 2	2018-09-11
Nalmefene salts as medicaments for reducing alcohol consumption or for preventing excessive alcohol consumption Grant 9,938,286 - De Diego April 10, 2	2018-04-10
Nalmefene Salts as Medicaments for Reducing Alcohol Consumption or for Preventing Excessive Alcohol Consumption App 20170275294 - De Diego; Heidi Lopez	2017-09-28
Nalmefene salts as medicaments for reducing alcohol consumption or for preventing excessive alcohol consumption Grant 9,725,458 - De Diego August 8, 2	2017-08-08
Novel Polymorphic Form of N-[2-(6-fluoro-lH-indol-3-yl)ethyl]-3-2,2,3,3-tetrafluoropropoxy)benzylam- ine hydrochoride for the treatment of Alzheimer's App 20170152227 - Andersen; Kristine Birklund ; et al.	2017-06-01
Vortioxetine Pyroglutamate App 20160368884 - de Diego; Heidi Lopez ; et al.	2016-12-22
Nalmefene Salts as Medicaments for Reducing Alcohol Consumption or for Preventing Excessive Alcohol Consumption App 20160152625 - De Diego; Heidi Lopez	2016-06-02
1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment Grant 9,227,946 - Faldt , et al. January 5, 2	2016-01-05
1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT.sub.3 and 5-HT.sub.1A activity for the treatment of cognitive impairment Grant 9,125,908 - Bang-Andersen , et al. September 8, 2	2015-09-08
1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT.sub.3 and 5-HT.sub.1A activity for the treatment of cognitive impairment Grant 9,125,909 - Bang-Andersen , et al. September 8, 2	2015-09-08
1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment Grant 8,969,355 - Bang-Andersen , et al. March 3, 2	2015-03-03
1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment App 20140315921 - Bang-Andersen; Benny ; et al.	2014-10-23
Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine Grant 8,598,348 - Nicolajsen , et al. December 3, 2	2013-12-03
Processes for 4-((1R,35)-6-Chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine or a salt thereof Grant 8,227,607 - de Diego , et al. July 24, 2	2012-07-24
Crystalline forms of a pharmaceutical compound Grant 8,076,320 - Rock , et al. December 13, 2	2011-12-13
Liquid Formulations Of Salts Of 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine App 20100105730 - Lasskogen; Gudrun ; et al.	2010-04-29
Crystalline base of trans-1-((1R,3S)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine Grant 7,648,991 - Bang-Andersen , et al. January 19, 2	2010-01-19
Crystalline Forms Of 4- [2- (4-methylphenylsulfanyl) -phenyl] Piperidine With Combined Serotonin And Norepinephrine Reuptake Inhibition For The Treatment Of Neuropathic Pain App 20090264465 - Bang-Andersen; Benny ; et al.	2009-10-22
Crystalline Base of Trans-1-((1R,3S)-6-Chloro-3-Phenylindan-1-Yl)-3,3-Dimethylpiperazine App 20080153848 - Bang-Andersen; Benny ; et al.	2008-06-26
Succinate and malonate salt of trans 4-(ir,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament App 20060281759 - de Diego; Heidi Lopez ; et al.	2006-12-14

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.